Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2019

CLL

View all
0:58
Update on CAR-NK cell therapy work at MD Anderson
William Wierda • 13 Jun 2019
1:23
Update on ERIC’s CLL studies and initiatives
Paolo Ghia • 13 Jun 2019

Multiple Myeloma

View all
2:46
CAR-T treatment outcomes: MM real-world data
Yi Lin • 13 Jun 2019
5:40
Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd
Philippe Moreau • 14 Jun 2019

Lymphoma

View all
1:38
The UK treatment landscape of mantle cell lymphoma
Simon Rule • 14 Jun 2019
2:25
JULIET: CRS and neurotoxicity in DLBCL
David Maloney • 13 Jun 2019

AML

View all
10:40
Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?
Christopher Hourigan • 14 Jun 2019
1:12
Heterogeneity in refractory AML
Christopher Hourigan • 15 Jun 2019

ALL

View all
3:33
CAR T-cells for ALL
Ulrich Jäger • 13 Jun 2019
1:01
Blinatumomab for pediatric ALL
Sara Ghorashian • 15 Jun 2019

MRD

View all
1:25
The role of MRD in CLL
Peter Hillmen • 14 Jun 2019
10:24
Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL
Kirsten Fischer • 14 Jun 2019

CML

View all
2:17
Current CML treatments: which TKI to choose?
Gianantonio Rosti • 13 Jun 2019
1:55
Long-term monitoring, adherence & endpoints in CML
Gianantonio Rosti • 13 Jun 2019

Sickle cell, PNH, ITP & more

View all
1:50
SAA treatment and QoL
Anita Hill • 13 Jun 2019
2:41
Advances in the treatment and prognosis of TTP
Paul Coppo • 13 Jun 2019
The content of VJHemOnc is intended for healthcare professionals